Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH

Am J Hematol. 2021 Jan;96(1):E5-E8. doi: 10.1002/ajh.26010. Epub 2020 Oct 21.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Databases, Factual*
  • Dexamethasone / administration & dosage
  • Disease-Free Survival
  • Female
  • Humans
  • Hydrazines / administration & dosage
  • Male
  • Middle Aged
  • Multiple Myeloma* / drug therapy
  • Multiple Myeloma* / mortality
  • Survival Rate
  • Triazoles / administration & dosage

Substances

  • Hydrazines
  • Triazoles
  • selinexor
  • Dexamethasone